With all the hoopla about Evista and breast cancer, the NYT points out one potential risk – buried at the bottom of the article:
Dr. Larry Norton, a breast cancer expert at Memorial Sloan Kettering Cancer Center in New York, said the greater risk of the early breast tumors with raloxifene was cause for concern. “They can eventually turn into invasive cancers,” he said.
Even if raloxifene does turn out to be less risky than tamoxifen when it comes to uterine cancer, the trade-off may still not be worth it, Dr. Norton said, because uterine cancer is much easier to detect and cure than breast cancer. Breast cancer is far more likely to be fatal.
